-
Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-3-13 Ting Wang, Yimo Feng
Lasmiditan holds important potential in treating migraine, but its ideal dose remains elusive. This meta-analysis is conducted based on aggregate data and aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for acute treatment of migraine attack.
-
Association of Anticholinergic Drug Burden With Cognitive and Functional Decline Over Time in Dementia With Lewy Bodies: 1-Year Follow-Up Study. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-3-13 Cemile Ozsurekci, Neslihan Kayahan Satis, Sultan Keskin Demircan, Mehmet Ilkin Naharci
The purpose of this study was to investigate the relationship between anticholinergic burden (ACB), and cognitive and functional alterations in patients with dementia of Lewy bodies (DLB) during a 1-year follow-up period.
-
Silymarin (Milk Thistle) Treatment of Adults With Gambling Disorder: A Double-Blind, Placebo-Controlled Trial. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-3-13 Jon E Grant, Corine Driessens, Samuel R Chamberlain
Data on the pharmacological treatment of gambling disorder are limited. Silymarin (derived from milk thistle) has antioxidant properties. The goal of the current study was to determine the efficacy and tolerability of silymarin in adults with gambling disorder.
-
A Patient With Minimally Conscious Syndrome Due to Cerebrovascular Accident Whose Symptoms Resolved With Zolpidem. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-3-13 Caleb Smack, Katherine Johnson, Noah Meester, Leah Shelton, Namrata Singh
In this report, we discuss the case of a patient with minimally conscious state (MCS) whose clinical condition significantly improved after Zolpidem therapy. We aim to provide supportive evidence for inclusion of zolpidem trials in patients with MCS.
-
Provider Experience With the Use of Ketamine for Refractory Status Epilepticus. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-02-01 Gabriela Tantillo, Nicole Davis, Justin Granstein, Ji Yeoun Yoo, Parul Agarwal, Kaitlin Reilly, Alexandra Reynolds, Gina Kayal, John Liang, Nathalie Jetté
Refractory status epilepticus (RSE) treated with anesthetic agents can be associated with complications including respiratory depression and hypotension. Ketamine is an emerging RSE treatment, but optimal dosing and timing are unknown. We studied provider attitudes and practices regarding the use of ketamine for RSE.
-
QTc Shortening on Electrocardiogram With Amitriptyline May Indicate No Effect on Pain Relief in Burning Mouth Syndrome. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-01-29 Takahiko Nagamine, Takeshi Watanabe, Akira Toyofuku
Burning mouth syndrome (BMS) is an intractable chronic pain disorder characterized by a burning sensation without organic abnormalities in the oral mucosa. Amitriptyline may be effective for BMS or, conversely, may exacerbate pain. QTc is necessary for monitoring psychotropic adverse effects, but it is not known if it is a predictor of efficacy for BMS. We investigated the efficacy of amitriptyline
-
Refractory Anti-N-Methyl-d-Aspartate Receptor Autoimmune Encephalitis Induced by Ovarian Teratoma: A Case Report. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-01-16 Rui Zhang, Xuemei Zhao, Wenjing Li, Yu Gao
Teratoma is a type of germ cell tumor that derived from early embryonic stem cells and germ cell lines, which can lead to a rare complication known as paraneoplastic encephalitis syndrome. Delayed removal of teratoma allows for continuing antigen presentation, inducing affinity maturation of the antibody and the generation of long-lived plasma cells that infiltrate both bone marrow and brain, which
-
Marked Decreased Tracer Binding in 123I-FP-CIT SPECT Scans From Lisdexafetamine Dismesylate Interaction: A Case Report. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-01-02 Toji Miyagawa, Cynthia Vernon, Scott A Przybelski, Hoon-Ki Min, Julie A Fields, Kejal Kantarci, Val Lowe, Bradley F Boeve
The objective of this case study is to raise awareness of potential 123I-FP-CIT SPECT interference by lisdexafetamine dimesylate, a prodrug of d-amphetamine.
-
Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Chart Review. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2024-01-02 Raíza Alves-Pereira, Mariana Fontes, Vivian Cordeiro, Igor D Bandeira, Daniela Faria-Guimarães, Samantha S Silva, Rodrigo P Mello, Gustavo C Leal, Aline S Sampaio, Lucas C Quarantini
Converging evidence supports the role of the glutamate, an excitatory amino acid neurotransmitter, in the pathophysiology of obsessive-compulsive disorder (OCD). Ketamine and esketamine, both noncompetitive N-methyl-d-aspartate antagonists, have emerged as a promising medication for this psychiatric disorder, given its possible efficacy with faster onset and good tolerability. The purpose of this retrospective
-
Effect of Levodopa on Heat Hypersensitivity and Complex Motor Parkinsonism. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-12-26 Eric Noyes, Ali H Rajput, Sarah Bocking, Alex Rajput
The aim of the study is to report a case with heat intolerance, complex motor fluctuations, and parkinsonism.
-
Comparison of Lasmiditan 200 mg Versus 100 mg for Migraine Patients: A Meta-analysis of Randomized Controlled Studies. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-12-18 Chuan Zhong, Xuanqin Zhang, Guoyong Qin, Jixiang Wu, Yongpan Tian
The ideal dose of lasmiditan for migraine is not clear. This meta-analysis aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients.
-
Efficacy and Safety of Rimegepant for Migraine Patients: A Meta-analysis of Randomized Controlled Studies. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-11-01 Chao Yang,Yue Zhang
OBJECTIVES Rimegepant may have some potential in treating migraine, and this meta-analysis aims to study the efficacy and safety of rimegepant for migraine patients. METHODS We have searched several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases and selected the randomized controlled trials comparing the efficacy of rimegepant versus placebo for migraine patients
-
A Case of Neuroleptic Malignant Syndrome in the Context of Lithium Toxicity and Aripiprazole Use. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-10-20 Autumn R Schultz,Sarina Singh,Carolyn E Linek-Rajapaksha,Heather R Goode,Adam J Fusick
OBJECTIVE Neuroleptic malignant syndrome (NMS) is a rare life-threatening condition that providers should be cognizant of when prescribing dopamine-receptor antagonists. Atypical antipsychotic agents were initially considered to have a lower risk of inducing the development of NMS compared with conventional antipsychotic. Considerable evidence, however, has suggested that atypical antipsychotics are
-
Consciousness Recovery in Traumatic Brain Injury: A Systematic Review Comparing Modafinil and Amantadine. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-10-19 Ali Seifi, Sina Hassannezhad, Reza Mosaddeghi-Heris, Arash Haji Kamanaj Olia, Ali Adib, Shaheryar Hafeez, Colleen Barthol
Acute traumatic brain injury is one of the most common causes of death and disability. Reduction in the level of consciousness is a significant complication that can impact morbidity. Glasgow Coma Scale (GCS) is the most widely used method of assessing the level of consciousness. Neurostimulants such as amantadine and modafinil are common pharmacologic agents that increase GCS in patients with brain
-
Involvement of Plasma Melatonin in Medication-Overuse Headache: A Cross-Sectional Study. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-10-19 Huimin Tao, Qi Wan, Mei Sun, Kefu Cai, Yan Song, Mingqing He, Jiabing Shen
Patients with medication-overuse headache (MOH) are often complicated with anxiety, depression, and sleep disorders and are associated with dependence behavior and substance abuse. Melatonin has physiological properties including analgesia, regulation of circadian rhythms, soporific, and antidepressant and affects drug preference and addiction. This study aimed to investigate the role of melatonin
-
The Utility of Methylphenidate for Fatigue in Long-Term Neurological Conditions: A Meta-analytical Review. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-10-19 Alexander James Hagan, Ram Kumar
Fatigue is a chronic and debilitating symptom of many long-term neurological conditions (LTNCs). Although methylphenidate provides some promise in alleviating fatigue in other clinical groups, little work has explored its potential utility within LTNCs. The current systematic review and meta-analysis evaluates the utility of methylphenidate for symptoms of fatigue in LTNCs.
-
An Examination of the Relationship Between Exposure to Bisphenol A and Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-10-16 Saliha Baykal,Ayşin Nalbantoğlu
OBJECTIVES Exposure to environmental toxic agents in the prenatal and/or postnatal periods may play in the acquired development of attention-deficit/hyperactivity disorder (ADHD) in groups with genetic risks. Bisphenol A (BPA) is a widely used industrial chemical with neurotoxic effects. This study examined the relationship between exposure to BPA and clinical ADHD. METHODS This cross-sectional, case-controlled
-
Galcanezumab in the Treatment of Migraine: A Narrative Review of Real-World Studies. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-09-23 Grazia Dell Agnello,Carlotta Buzzoni,Amalia Antenori,Federico Torelli,Claudia Altamura,Fabrizio Vernieri
OBJECTIVES Randomized controlled trials (RCTs) have established the efficacy of galcanezumab, an antibody binding calcitonin gene-related peptide (CGRP) ligand, in the preventive treatment of migraine. The objective was to summarize real-world data evaluating galcanezumab in the preventive treatment of migraine, to complement RCT results with evidence observed in clinical practice. METHODS A literature
-
Neuroleptic Malignant Syndrome in Patients With Dementia: Experiences of A Single Memory Clinic. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-09-19 Ahmet Turan Isik, Derya Kaya, Mehmet Selman Ontan, Feyza Mutlay, Esra Ates Bulut, Fatma Sena Dost, Neziha Erken, Ali Ekrem Aydin
Neuroleptic malignant syndrome (NMS) is a life-threatening condition that occurs as an adverse reaction to antipsychotic and antiemetic agents or sudden withdrawal of dopaminergic medications. Given the metabolic and functional reserves and the comorbidities in older adults, NMS may show an atypical course.
-
Changes of Serum C-Reactive Protein Level in Patients With Depressive Disorders After Treatment With Agomelatine Combined With Aerobic Exercise and Its Significance. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-09-12 Zhuping Sun, Silu Chen, Hui Zhang, Xiaoqing Gu, Haiyan Ge, Jinglei Chen
Depressive disorders constitute a series of debilitating diseases. This study investigated the therapeutic effect of agomelatine (AG) combined with aerobic exercise (AE) on patients with moderate-severe depression (MSD) and the changes of the serum C-reactive protein (CRP) level in patients after treatment as well as its significance.
-
Undiagnosed Lambert-Eaton Myasthenic Syndrome in the Era of Sugammadex: A Case Report. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-09-12 Jenny J Yoon, Alexandra L Anderson, Adam D Niesen
In this case report, we discuss the rare manifestation of prolonged neuromuscular blockade in a patient with history of small cell lung cancer and undiagnosed Lambert-Eaton myasthenic syndrome (LEMS) who had previously received succinylcholine for general anesthesia without incident but subsequently exhibited prolonged neuromuscular blockade during a laparoscopic procedure. We aimed to emphasize the
-
Effects of Amantadine Sulfate on Motor Impairment and Execution of Motor Sequences in Patients With Parkinson Disease. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-07-31 Thomas Müller, Wilfried Kuhn
Intravenous application of amantadine sulfate induces a rapid improvement of motor behavior in patients with Parkinson disease.
-
Three Cases of Myoclonus Secondary to Ciprofloxacin: "Ciproclonus". Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-07-27 Hamna Javed, Hossam Tharwat Ali, Ziad Ashraf Soliman, Ana Leticia Fornari Caprara, Jamir Pitton Rissardo
Ciprofloxacin is a fluoroquinolone that is used for bacterial infections involving different systems. In some cases, ciprofloxacin was reported to induce myoclonus.
-
Status Cataplecticus Induced by an Abrupt Duloxetine Withdrawal-A Case Report. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-07-18 Marek Cierny, John Feemster, Mohsin Hamid, Humberto A Battistini
In persons with narcolepsy type 1, sudden withdrawal of antidepressants can cause status cataplecticus. We describe a 77-year-old female patient with long-standing history of narcolepsy type 1 complaining of recurrent short sudden episodes of whole-body paralysis, with preserved consciousness and memory. Episodes started an hour after her family invited her to celebrate Mother's Day. One week prior
-
Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-07-18 Erfaneh Hajian Tilaki, Alireza Hasanzadeh, Mohammadreza Shalbafan, Hossein Sanjari Moghaddam, Ahmad Shamabadi, Mahsa Boroon, Shahin Akhondzadeh
Reboxetine is a potent and selective norepinephrine reuptake inhibitor that was effective in combination with citalopram for resistant obsessive-compulsive disorder (OCD). This study aims to assess its effectiveness and tolerability in combination with fluoxetine in treating OCD.
-
Correlation of Obesity and Clinical Characteristics in Drug-Naive First-Episode Patients With Schizophrenia. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-07-04 Na Li, Hua Xue, Yong Li, Minglong Gao, Ming Yu, Cuixia An, Chaomin Wang
This study was aimed at investigating the prevalence of obesity in drug-naive first-episode (DNFE) patients with schizophrenia and its association with metabolic parameters, psychopathological symptoms, and cognitive function.
-
Amantadine for Refractory Tremor in Parkinson Disease and Other Indications: A Chart Review With Long-Term Follow-up. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-07-04 Joseph H Friedman
The aim of this study was to determine how amantadine was used in a movement disorders clinic and how effective it was.
-
Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-06-21 Mauro Scala, Laura Biondi, Alessandro Serretti, Chiara Fabbri
Obsessions, compulsions, and stereotypes are common psychopathological manifestations of obsessive-compulsive, psychotic, and autism spectrum disorders (ASDs). These nosological entities may be present in comorbidity, with relevant clinical difficulties in the differential diagnosis process. Moreover, ASDs are a complex group of disorders, with a childhood onset, which also persist into adulthood and
-
Inflammation Markers Among Schizophrenia Patients Who Use Cannabis. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-06-20 Jonathan Fridman, Esther Bloemhof-Bris, Shira Weizman, Tal Kessler, Dorit Porat, Amos Ivry, Aviva Wolf, Rafael Stryjer, Assaf Shelef
The mechanism of inflammation of the immune system, for example, such circulatory markers as the neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV), has been shown in many studies to be associated with schizophrenia. In addition, it has been shown that the cannabidiol component reduces the activation of the acquired immune system. This study examined the differences in the levels of
-
Aripiprazole-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Case Study. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-06-20 Christian J Coulson, Marie Yrastorza-Daghman
The use of medications in management of disease is an integral part of treatment to patients in both the inpatient and outpatient setting; however, these medications often have risk of adverse effects associated with their benefits of use. Adverse cutaneous reactions are one of the most frequent types of adverse drug reactions. Two major phenotypes of cutaneous adverse drug reactions are toxic epidermal
-
Medication Overuse Headache, Chronic Migraine and Monoclonal Antibodies Anti-CGRP: A Real-World Study. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-06-20 Abouch Krymchantowski, Carla Jevoux, Ana Gabriela Krymchantowski, Raimundo Pereira Silva-Néto
Medication overuse headache (MOH) in chronic migraineurs may be a cause or consequence of the overuse of symptomatic medications for headache attacks. It is highly prevalent in tertiary centers. We compared the efficacy of 3 anti-CGRP monoclonal antibodies with traditional pharmacological agents in patients with chronic migraine (CM) and MOH.
-
Botulinum Toxins and Zinc: From Theory to Practice-A Systematic Review. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-06-20 Farid Mallat, Jerome Kaikati, Elio Kechichian
The aims of this study were to determine whether zinc supplementation affects botulinum toxin's effect and longevity and to establish a transition from the molecular to the clinical aspect.
-
ABCB1 Gene Polymorphisms Are Closely Associated With Drug-Resistant Epilepsy: Evidence Based on 377 Subjects in Chinese Pediatric Patients. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-06-07 Ting Zhao, Hong-Jian Li, Jing Yu, Hui-Lan Zhang, Jie Feng, Ting-Ting Wang, Lu-Hai Yu, Yan Sun
P-glycoprotein plays a role in drug resistance of epileptic patients by limiting gastrointestinal absorption and brain access to antiseizure medications. This study aimed to evaluate the association between ABCB1 polymorphisms and drug resistance in epileptic pediatric patients.
-
Characteristics and Treatments of Coronavirus Disease 2019 Patients Presenting With Persistent Hiccups: A Scoping Review. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-05-22 Michael Boulis, Mary Boulis, Marianne Cosgrove, Ken He
Over the time of the pandemic, coronavirus disease 2019 (COVID-19) has surprised us with a growing list of atypical presentations, one of which is persistent hiccups that last more than 48 hours. The aim of this review is to investigate the characteristics of COVID-19 patients presenting with persistent hiccups and explore treatments used to control persistent hiccups in such cases.
-
Serum Angiotensin-Converting Enzyme Methylation Level and Its Significance in Patients With Comorbid Major Depressive Disorder and Hypertension Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-04-26 Gulibakeranmu Abula, Jinxian Li, Rui Ma, Tin Zhang, Adila Aji, Yi Zhang
Objective Major depressive disorder (MDD) often coexists with hypertension (HYT). DNA methylation has elicited vital functionality in their development. Angiotensin-converting enzyme (ACE) is a vital enzyme in blood pressure. This study investigated the effect of ACE methylation on depression and HYT severity in patients with comorbid MDD and HYT (MDD + HYT). Methods A total of 119 patients (41 men
-
Medical Cannabis in the Treatment of Parkinson’s Disease Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-04-19 Traci S. Aladeen, Anna G. Mattle, Kory Zelen, Moustafa Mesha, Michelle M. Rainka, Tanya Geist, Bennett Myers, Laszlo Mechtler
Objectives Medical cannabis (MC) has recently garnered interest as a potential treatment for neurologic diseases, including Parkinson’s disease (PD). A retrospective chart review was conducted to explore the impact of MC on the symptomatic treatment of patients with PD. Methods Patients with PD treated with MC in the normal course of clinical practice were included (n = 69). Data collected from patient
-
The Effect of Adding Curcumin to Sertraline in the Treatment of Severe Major Depressive Disorder: A Randomized, Double-Blind Clinical Trial. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-04-19 Ali Talaei, Reza Noori, Amir Rezaei Ardani, Amir Hooshang Mohammadpour, Zohre Azimipoor, Fahimeh Afzaljavan
Major depressive disorder (MDD) is a chronic and debilitating disease influenced by inflammatory processes in the brain. Some evidence has represented the adding curcumin as a complementary regime to the standard medication in treating depressive symptoms. However, limited clinical trials have been conducted on the antidepressants effects of curcumin in MDD patients. Therefore, this study aimed to
-
Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-04-11 Mónica Santos, João Sequeira, Pedro Abreu, Rui Guerreiro, Mariana Santos, João Ferreira, Marisa Brum, Filipa Ladeira, Lia Leitão, Rafael Dias, Maria José Sá, Vasco Salgado, Carlos Capela, João de Sá
Objectives Cladribine is a selective and oral immunological reconstitution treatment, approved in Europe for very active multiple sclerosis (MS) with relapses. Aims were to assess the safety and effectiveness of cladribine in real-world setting, during treatment follow-up. Methods This was a multicentric, longitudinal, observational study with retrospective and prospective data collection of clinical
-
Precision Medicine in Epilepsy Management; GET Application (Gene, Epilepsy, Treatment) Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-31 Ali A. Asadi-Pooya
Objectives The aim was to develop a prototype of an application (app) that identifies the significance of discovered genes for further consideration in the treatment plan of patients with epilepsy (precision medicine). Methods MEDLINE was systematically searched for related publications from inception to April 1, 2022. The following search strategy was implemented (title/abstract): “epilepsy” AND
-
The Downside of Botulinum Injections for Anterocollis: A Case Series and a Review of the Literature Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-13 Gilad Yahalom, Eden Atlan, Amir Janah, Melania Dominko, Ilana Israel, Gustavo Rajz, Stefan Mausbach, Roni Eichel
Objectives This is a case series and a review of the literature of therapeutic outcomes of botulinum toxin (BT) injections for anterocollis. Methods Data collected included gender, age, age at onset, muscles targeted, and doses injected. Routine forms were filled out during each visit: Patient Global Impression of Change, Clinician Global Impression of Severity, Tsui scale. The effect duration and
-
A Case of Oral Cenesthopathy Treated With the Combination of Brexpiprazole and Mirtazapine Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-10 Yojiro Umezaki, Haruhiko Motomura, Rui Egashira, Akira Toyofuku, Toru Naito
Objectives Oral cenesthopathy is an uncomfortable and bizarre oral sensation without corresponding organic findings. Although some treatment options, including antidepressants and antipsychotic drugs, have been reported to be effective, the condition remains refractory. Here, we report a case of oral cenesthopathy treated with brexpiprazole, a recently approved D2 partial agonist. Methods and Results
-
Effects of Exercise on Testosterone and Implications of Drug Abuse: A Review Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-07 Brendan Perreault, Nikki Hammond, Panayotis K. Thanos
Objective Research points to exercise having a positive effect in fighting relapse and use of drugs of abuse. Through conducting this research, differences have been observed in the effects of exercise on drug abuse between sexes. Many of the studies found that exercise tends to cause a more profound effect in blocking drug relapse or reinstatement in males when compared with females. Methods Our
-
A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-07 Charles Springer, Robert Rodgers, Gina Vivino, Saritha Attanagoda, Charles Dylan Miks
Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. Here, we describe the case of a 32-year-old woman with a pituitary prolactinoma who was treated with cabergoline for 1 year, during which time she developed delusions. We also discuss the use of aripiprazole to mitigate the psychotic symptoms, while maintaining the efficacy of cabergoline treatment
-
Efficacy and Safety of Dl-3-n-Butylphthalide Combined With Human Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Yaqian Zhang, Feng Zhou, Huiqing Li, Junjie Lei, Zhihuai Mo, Guangrong Li, Junfeng Wang
Objectives Intravenous thrombolysis and mechanical endovascular thrombectomy are recommended for patients whose stroke onsets are within the first 6 hours; however, patients beyond this time window have very limited options. Dl-3-n-butylphthalide (NBP) and human urinary kallidinogenase (HUK) have shown potential clinical benefits in the treatment of acute ischemic stroke (AIS) patients. This research
-
Effect of Adding l-Carnitine to Risperidone on Behavioral, Cognitive, Social, and Physical Symptoms in Children and Adolescents With Autism: A Randomized Double-Blinded Placebo-Controlled Clinical Trial Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Fereshteh Shakibaei, Danial Jelvani
Objectives The present research aimed to evaluate the effect of adding l-carnitine to risperidone in treating children and adolescents with autism spectrum disorder (ASD). Methods In this randomized controlled clinical trial study, 50 ASD children and adolescents were divided into 2 groups: those receiving l-carnitine and risperidone (n = 25) and those receiving placebo and risperidone (n = 25).
-
Seizure Occurring During Baclofen Monotherapy for Phenibut Withdrawal Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Amber Patt, Haley Fox, Lauren Wells, Jillian Theobald, Ryan Feldman
Objective Phenibut is a widely available gamma-aminobutyric acid B receptor agonist. When taken chronically, phenibut causes dependence and subsequent withdrawal if stopped. Baclofen, a gamma-aminobutyric acid B receptor agonist structurally related to phenibut, has been used to manage phenibut withdrawal (PW), although baclofen doses for PW are not well defined and may exceed Food and Drug Administration–approved
-
The Clinical Development of Levodopa Inhalation Powder Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Robert A. Hauser, Peter A. LeWitt, Cheryl H. Waters, Donald G. Grosset, Burkhard Blank
Oral levodopa is the most effective treatment for Parkinson disease, but OFF periods emerge over time. Gastrointestinal dysfunction and food effects impact levodopa absorption, contributing to unpredictable control of OFF periods. Inhaled levodopa powder (Inbrija) is approved for on-demand treatment of OFF periods in patients receiving oral levodopa–dopa decarboxylase inhibitors. The 84-mg dose is
-
Perampanel: Medical Alternative for Essential Tremor? Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Lola Díaz-Feliz, Cici Feliz-Feliz, Javier Del Val, Marta Ruiz-López, Pedro J. García-Ruiz
Objectives The aim of this study was to assess the safety and efficacy of perampanel in patients with refractory essential tremor (ET). Methods We recruited patients from our movement disorders clinic with the diagnosis of severe refractory ET, and perampanel 4 mg at night was initiated. Assessments were conducted at baseline and after 1 month of treatment with perampanel 4 mg/d. Details about tolerance
-
Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Peter LeWitt, Grace S. Liang, C. Warren Olanow, Karl D. Kieburtz, Roland Jimenez, Kurt Olson, Olga Klepitskaya, Gordon Loewen
Objectives Levodopa (LD) administered with dopa decarboxylase inhibitor is predominantly metabolized in the periphery by catechol-O-methyltransferase (COMT) to 3-O-methyldopa (3-OMD). Catechol-O-methyltransferase inhibition can improve treatment outcomes by decreasing variability in circulating LD concentrations. Opicapone is a once-daily COMT inhibitor approved in the US adjunctive to carbidopa (CD)/LD
-
Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Ozge Gonul Oner, Hasan Can Gudek, Ozdem Erturk Cetin, Serkan Demir
Objective Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe. However, if toxin enters the vascular space and gets through to peripheral cholinergic nerve terminals, it may lead to iatrogenic botulism. Method We presented a patient
-
Aripiprazole Used to Treat Capgras Syndrome in an Adolescent Diagnosed With Autism Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Saliha Baykal, Caner Mutlu
Objectives This report discusses the emergence, clinical appearance, and treatment of the rare entity Capgras syndrome (CS) in an adolescent diagnosed with autism. Methods After a brief introduction to the CS, we conduct a detailed description of the case and review, after a search on the PubMed database, the known pathophysiology, psychiatric disorders associated with the onset of this syndrome
-
Therapeutic Drug Monitoring of Lacosamide: Is 10 to 20 mg/L a Suitable Reference Range for Patients With Epilepsy? Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-03-01 Sara Otero Torres, Roser Juvany Roig, Mercè Falip Centellas, Miriam Casellas Gibert, Mónica Estopiñá Antolí, Raül Rigo Bonnin, Jacint Xavier Sala-Padro, Ramón Jódar Massanés
Objectives The reference range for lacosamide (LCM) has been updated from 1 to 10 mg/L to 10 to 20 mg/L. Historically, LCM range was defined from trough-level measurements, but the newer ranges were obtained from peak-level measurements. The purpose of the study was to evaluate the relationship between LCM plasma levels higher than 10 mg/L and the incidence of adverse effects. Methods This was a
-
Clinically Determined Asterixis Is Markedly Increased in Patients Taking Clozapine. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-02-15 Joseph H Friedman
-
Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-01-01 Jinrong Lian, Jiahe Wang, Xiang Li, Siyuan Yang, Hang Li, Yi Zhong, Heng Gao, Gang Chen
Objective The aim of this study was to assess the efficacy of different dosage regimens of tanezumab among individuals living with chronic low back pain (CLBP). Methods PubMed, Embase, The Cochrane Library, and other databases were searched from inception until August 2021. Randomized controlled trials investigating the efficacy and safety of tanezumab in individuals with CLBP were included. Data
-
Pharmacological Strategies for Stroke Intervention: Assessment of Pathophysiological Relevance and Clinical Trials Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-01-01 Geetesh Verma, Deepaneeta Sarmah, Aishika Datta, Avirag Goswami, Nikita Rana, Harpreet Kaur, Anupom Borah, Sudhir Shah, Pallab Bhattacharya
Objectives The present review describes stroke pathophysiology in brief and discusses the spectrum of available treatments with different promising interventions that are in clinical settings or are in clinical trials. Methods Relevant articles were searched using Google Scholar, Cochrane Library, and PubMed. Keywords for the search included ischemic stroke, mechanisms, stroke interventions, clinical
-
Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-01-01 Qiang Deng, Sihong Tao, Hui Huang, Qikun Lv, Wei Wang
Introduction Chloroquine supplementation may show some potential in improving the efficacy for glioblastoma, and this meta-analysis aimed to identify the efficacy of chloroquine supplementation for patients with glioblastoma. Methods Several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases have been systematically searched through August 2022, and we included
-
Lithium-Induced Dysgeusia and Hyposmia: A Case Report and a Literature Review Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-01-01 Odete Nombora, Ana Samico, Ângela Venâncio
Background Bipolar disorder is a complex psychiatric disorder where long-term treatment is crucial to maintain stabilization. Although largely well tolerated, lithium has a wide spectrum of adverse effects in different organs and seems to also cause taste and smell disorders, which remain rare and not largely described. We aim to present a rare case of hyposmia and dysgeusia secondary to lithium treatment
-
A Case of Multidrug-Resistant Lance-Adams Syndrome Successfully Treated With Phenobarbital Clin. Neuropharmacol. (IF 1.0) Pub Date : 2023-01-01 Nurşah Yeniay Süt, Miraç Yıldırım, Ömer Bektaş, Tanıl Kendirli, Serap Teber
Objective Lance-Adams syndrome is a rare but devastating disorder characterized by rest, action, and stimulus-sensitive myoclonus after cardiorespiratory arrest. We aimed to present a case of multidrug-resistant Lance-Adams syndrome that was successfully treated with oral phenobarbital therapy. Method and Results We report a previously healthy 11-year, 6-month-old boy was referred to our pediatric
-
The Efficacy and Safety of Adjuvant Lomustine to Chemotherapy for Recurrent Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2022-11-17 Xiaojuan Fu, Dijian Shi, Yimo Feng
Lomustine is regarded as 1 common anti-vascular endothelial growth factor agent. The efficacy of adjuvant lomustine to chemotherapy remains controversial for recurrent glioblastoma. We conduct this meta-analysis to explore the influence of adjuvant lomustine on treatment efficacy of recurrent glioblastoma.
-
Efficacy of Valproic Acid Against Coronavirus Disease 2019 Infection or Severity: A Pilot Study. Clin. Neuropharmacol. (IF 1.0) Pub Date : 2022-11-17 Mohsen Farazdaghi, Seyed Mohammad Ali Razavizadegan, Mahnoosh Moghimi, Ali A Asadi-Pooya
The purpose of the current study was to investigate whether taking valproic acid (VPA) was protective against coronavirus disease 2019 (COVID-19) infection or severity in patients with epilepsy.